Interventional Neuroradiology
|
Abbott Northwestern Hospital Direct Line |
For Providers
The Interventional Neuroradiology department of Consulting Radiologists, Ltd. practice in affiliation with the Neuroscience Institute and Minneapolis Heart Institute at Abbott Northwestern Hospital. Our physicians work closely with highly experienced neurosurgeons, neurologists, neuro-oncologists, intensivists, interventionalists, and otolaryngologists to provide comprehensive neurological care.
Patient Follow-Up Process
Imaging and or clinic follow up recommendations are communicated to the patient and referring physicians at the time of evaluation or treatment.
Aneurysm Patient Follow-Up
Brain aneurysm follow-up can vary depending on the aneurysm location, size, morphology, patient age, and individual patient history. Generally, follow up for an endovascularly treated brain aneurysm is a six month formal catheter cerebral angiogram. If stable, a 2 and 4 year MR angiogram of the brain will be performed.For those patients whose aneurysms are unable to be treated endovascularly, a neurosurgical consultation will be arranged. In patients who elect not to have their brain aneurysm treated, surveillance imaging is often recommended and arranged as deemed appropriate.
A considerable number of aneurysms do not need to be treated because of their extradural location. In younger patients, we feel that these should be monitored. We will arrange for follow-up with either MRA or CTA and contact the patient with the results.
Request Films
To request copies of a patient’s films, please contact us directly at (612) 863-4808 or you may contact the Film Library at Abbott Northwestern Hospital at (612) 863-4799.
Special Device Information
MRI Compatibility
Provided by device manufacturers
- GDC Coils for aneurysm embolizations, (Information from Stryker Neurovascular Inc.)
- The detachable platinum coils can be scanned safely under the following conditions:
- Static magnetic field of 3 Tesla or less
- Spatial Gradient field of 720 Gaus or less
- Maximum average specific absorption rate (SAR) of 3W/kg for 15 minutes of scanning.
- *Carotid Stents (Information from ev3 Neurovascular, eV2 inc. for the Protege Stent)
- In non-clinical testing, the stent has been shown to be MR Conditional1 at field strengths of 3 Tesla or less and a maximum whole body average specific absorption rate (SAR) of 3 W/kg for 20 min of MR.
- The stent should not migrate in this MR environment. Non-clinical testing has not been performed to rule out the possibility of stent migration at field strengths higher than 3 Tesla.
- In this testing, the stent produced a temperature rise of less than 0.54°C at a maximum whole body averaged specific absorption rate (SAR) of 3 W/kg for 20 minutes of MR. The effect of heating in the MRI environment for overlapping stents or stents with fractured struts is not known.
- MR image quality may be compromised if the area of interest is in the exact same area or relatively close to the position of the stent.
- *Wingspan Intracranial Stent for intracranial stenosis (Stryker Neurovascular-formerly Boston Scientific Corp. Neurovascular)
- MRI compatible in MRI systems operating at field strengths or 3.0 Tesla or less
- *Neuroform Stent for aneurysm embolizations (Stryker Neurovascular (formerly Boston Scientific Corp. Neurovascular)
- Neuroform Stent, single configuration only, no overlapped or fractured stents have been tested for RF heating interaction.
- Safe for horizontal static magnetic fields 3 T and less Static magnetic field gradient | B | < 92 T/m (extrapolated) Static magnetic field gradient product | B | . |B |<235 T2/m (extrapolated) Safe for 1.5 and 3 Tesla based on in-vitro RF heating tests: Recommendation: Local body SAR for using the body coil ≤ 2.3 W/kg (1.5 T) with maximum continuous scan duration of 16:59 min. ≤ 2.1 W/kg (3 T) with maximum continuous scan duration of 20.00 min. Recommendation: Local head SAR for using the head coil (transmit/receive): ≤ 2.6 W/kg (1.5 T) with maximum continuous scan duration of 16:40 min. ≤ 1.7 W/kg (3 T) with maximum continuous scan duration of 20:00 min. Measurement inaccuracies and additional safety margins should be taken into account. (Recommended local SAR is based on theoretical extrapolation to maintain localized temperature increase ≤1˚C based on in vitro test results, valid for test configuration only). Note: the whole body averaged (WBA) and/or head averaged software displayed SAR is inappropriate to scale exact local temperature increases. Local SAR can deviate and result in much higher values than the WBA-SAR Software displayed. No other RF heating testing than 1.4 Tesla & 3 Tesla only was performed. Gradient magnetic fields: stimulation level of ~76% (3 Tesla Magnetom™ Trio, Siemens Medical Solutions MR system) and information of stimulation display dB/dt limit = 20 T/s (1.5 Tesla Signa Excite™, General Electric Medical) were used during RF heating tests. No tests have been performed regarding possible nerve or other tissue stimulation. Neuroform stent has not been tested in combination with other devices MR image artifacts affect the direct device surrounding. Magnetom is a trademark of Siemens Corporation. Signa and Excite are trademarks of General Electric Company.Neuroform EZ™ Stent System, Boston Scientific, One Boston Scientific Place, Natick, MA 01760-1537
- Onyx Liquid Embolic for malformations (AVM/AVF) and *aneurysms (ev3 Neurovascular, ev3 Inc.)
- Onyx® is a non-adhesive liquid embolic agent comprised of EVOH (ethylene vinyl alcohol) copolymer dissolved in DMSO (dimethyl sulfoxide), and suspended micronized tantalum powder to provide contrast for visualization under fluoroscopy.
- This embolic material is MRI compatible.
*Many of these devices require use of dual-antiplatelet therapy prior to and for a period following implantation of these devices. Please contact us prior to discontinuing these medications.
Physician Resources
- Ischemic Stroke Neurologic Emergency Treatment Network Protocols
- Carotid Arterty Stenosis Protocols
- Cerebral Venous Thrombosis Protocols
- Neuroscience Institute Outcomes Report 2009